Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
Hope Cancer Center
mi
from
Terre Haute, IN
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
Hope Cancer Center
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
Cancer Center of Kansas
mi
from
Wichita, KA
Click here to add this to my saved trials
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
Virtua Memorial (Regional Cancer Care Associates of Mount Holly)
mi
from
Mount Holly, NJ
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
Virtua Memorial (Regional Cancer Care Associates of Mount Holly)
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
Mercy Clinic Oncology and Hematology
mi
from
Oklahoma City, OK
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
Mercy Clinic Oncology and Hematology
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/10/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/10/2018
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Status: Enrolling
Updated:  1/10/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Status: Enrolling
Updated: 1/10/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Status: Enrolling
Updated:  1/10/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation
Status: Enrolling
Updated: 1/10/2018
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
An Open-label, Prospective, Randomized, Pilot Clinical Study to Study the Efficacy of MEDIHONEY® Rinses Compared to Intranasal Corticosteroid Rinses in Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
Status: Enrolling
Updated:  1/12/2018
University of Vermont Medical Center
mi
from
Burlington, VT
The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
An Open-label, Prospective, Randomized, Pilot Clinical Study to Study the Efficacy of MEDIHONEY® Rinses Compared to Intranasal Corticosteroid Rinses in Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery
Status: Enrolling
Updated: 1/12/2018
University of Vermont Medical Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Gilbert, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Mesa, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Pasadena, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Santa Barbara, CA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Altamonte Springs, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Miami, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ocala, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ocala, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Orlando, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Tampa, FL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Niles, IL
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Niles, IL
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lafayette, IN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lafayette, IN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Ames, IA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Ames, IA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New Orleans, LA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Lincoln, NE
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Omaha, NE
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Henderson, NV
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Albany, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Binghamton, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Binghamton, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bronx, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Hudson, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Hudson, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Johnson City, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Johnson City, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
New York, NY
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Charleston, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Easley, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Easley, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Greer, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Sumter, SC
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials